Company intelligence / Profile preview
Omega Therapeutics
Cambridge, Massachusetts, United Statesomegatherapeutics.com ↗
- Ownership
- Public · OMGA
- Employees
- ~94
- Development stage
- Other
01
Overview
Completed Phase 1 MYCHELANGELO trial of OTX-2002 showed 50% disease control rate in HCC patients, demonstrating ability to induce prespecified changes in epigenetic signatures that alter gene expression with high specificity[8][9]
- Therapeutic areas
- GastroenterologyCardiovascularMetabolic DisordersEndocrinologyOncology
- Modalities
- Programmable epigenomic mRNA medicinesepigenomic controllers (ECs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Novo Nordisk (research collaboration for cardiometabolic therapies)
Beyond the preview
Go deeper on Omega Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omega Therapeutics.